← 홈

CGT

1,235개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-6 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 1,235개
CGTBiologicstaleChinese PLA General HospitalPhase 2

GPC3-CART cells (GPC3-CART cells)

Hepatocellular Carcinoma (HCC) · Carcinoma, Hepatocellular

#CarcinomaHepatocellular#CGT#Phase2#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleOriCell Therapeutics Co., Ltd.Phase 1

GPRC5D-CAR-T (GPRC5D-CAR-T)

Multiple Myeloma · GPRC5D

#GPRC5D#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
CGTAAVBiologicstaleFederal State Budget Institutio…Phase 2

GT-UGT1A1-AAV8-02 (GT-UGT1A1-AAV8-02)

Crigler-Najjar Syndrome Type I · Crigler-Najjar Syndrome Type I

#Crigler-NajjarSyndromeTypeI#CGT#Phase2#세포유전치료#CAR-T+2
임상시험 1상태 RECRUITING
CGTBiologicstaleInstitut National de la Santé E…Phase 1

Gene Therapy product CYL-02 = plasmid DNA pre-complexed to linear polyethylenimine encoding sst2 + dck::umk genes (Gene Therapy product CYL-02 = plasmid DNA pre-complexed to linear polyethylenimine encoding sst2 + dck::umk genes)

Pancreatic Adenocarcinoma · Pancreatic Adenocarcinoma

#PancreaticAdenocarcinoma#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 1상태 ACTIVE
CGTBiologicstaleNanoscope Therapeutics Inc.Phase 2

Gene Therapy-vMCO-010 (Gene Therapy-vMCO-010)

Stargardt Disease · Stargardt Disease

#StargardtDisease#CGT#Phase2#세포유전치료#CAR-T+2
임상시험 1상태 ACTIVE
CGTAAVBiologicstaleTippi MackenziePhase 1

Gene Transfer with an AAV9 Vector Expressing Human ß-galactosidase (Gene Transfer with an AAV9 Vector Expressing Human ß-galactosidase)

GM1 Gangliosidoses; GM1 Gangliosidosis, Type I · GM1 Gangliosidoses

#GM1Gangliosidoses#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleShanghai Zhongshan HospitalPhase 1

First dose group (Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :1.0×10^8, Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :1.0×10^8(First dose group))

HCC · HCC

#HCC#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 1상태 RECRUITING
CGTBiologicstaleGuangzhou JOYO Pharma Co., LtdPhase 1

Second dose group (Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :2.5×10^8, Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :2.5×10^8(Second dose group))

HCC · HCC

#HCC#CGT#Phase1#세포유전치료#CAR-T+2
효능 ORR 38%임상시험 1상태 RECRUITING
CGTBiologicstaleShanghai Zhongshan HospitalPhase 1

Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :5.0×10^8（Third dose group） (Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :5.0×10^8（Third dose group）)

HCC · HCC

#HCC#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 1상태 RECRUITING
CGTBiologicstaleGenSight BiologicsPhase 2

Gene therapy: GS030-DP AND Medical device: GS030-MD (Gene therapy: GS030-DP AND Medical device: GS030-MD)

Non-syndromic Retinitis Pigmentosa · Non-syndromic Retinitis Pigmentosa

#Non-syndromicRetinitisPigmentosa#CGT#Phase2#세포유전치료#CAR-T+2
임상시험 1상태 RECRUITING
CGTBiologicstaleChildren's Hospital Medical Cen…Phase 2

Gene-Corrected Macrophages administered by bronchoscopic instillation (Gene-Corrected Macrophages administered by bronchoscopic instillation)

Hereditary Pulmonary Alveolar Proteinosis · Hereditary Pulmonary Alveolar Proteinosi

#HereditaryPulmonaryAlveolarProte#CGT#Phase2#세포유전치료#CAR-T+2
임상시험 1상태 RECRUITING
CGTBiologicstaleWugen, Inc.Preclinical

Genetic: WU-CART-007 (Genetic: WU-CART-007)

T-cell Acute Lymphoblastic Leukemia; T-cell Lymphoblastic Lymphoma · T-cell Acute Lymphoblastic Leukemia

#T-cellAcuteLymphoblasticLeukemia#CGT#Preclinical#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
CGTBiologicstaleMuscular Dystrophy AssociationPhase 1

Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort (Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort)

Muscular Dystrophies · Muscular Dystrophies

#MuscularDystrophies#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 1상태 ACTIVE
CGTBiologicstaleFate TherapeuticsPreclinical

Genetically engineered NK cells (Genetically engineered NK cells)

Hematological Malignancy · Hematological Malignancy

#HematologicalMalignancy#CGT#Preclinical#세포유전치료#CAR-T+2
효능 ORR 0%임상시험 1상태 DISCONTINUED
CGTBiologicstaleChinese PLA General HospitalPhase 1

GoFast CD19 CAR T Cells (GoFast CD19 CAR T Cells)

Relapsed or Refractory Large B-cell Lymphoma · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstaleHadassah Medical OrganizationPhase 2

HBI 0201-ESO TCRT (HBI 0201-ESO TCRT)

Sarcoma, Synovial; Sarcoma,Soft Tissue · Sarcoma, Synovial

#SarcomaSynovial#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleFuda Cancer Hospital, GuangzhouPhase 2

HER-2-targeting CAR T Cells infusion (HER-2-targeting CAR T Cells infusion)

Breast Cancer · Breast Cancer

#BreastCancer#CGT#Phase2#세포유전치료#CAR-T+2
임상시험 1상태 DISCONTINUED
CGTBiologicstaleBaylor College of MedicinePhase 1

HER.CAR CMV-specific CTLs (HER.CAR CMV-specific CTLs)

Glioblastoma Multiforme (GBM) · Glioblastoma Multiforme (GBM)

#GlioblastomaMultiformeGBM#CGT#Phase1#세포유전치료#CAR-T+2
임상시험 1상태 ACTIVE
CGTBiologicstaleChildren's Oncology GroupPhase 1

HER2 Specific CAR T Cell (HER2 Specific CAR T Cell)

Ependymoma · HER2

#HER2#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 RECRUITING
CGTBiologicstalesu haichuanPreclinical

HER2-E-CART cells (HER2-E-CART cells)

Solid Tumor · HER2

#HER2#CGT#Preclinical#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE

45 / 62 페이지

← 이전다음 →